Publicaciones en las que colabora con José Ángel Ruiz Ortega (18)

2024

  1. Automated procedure to detect subtle motor alterations in the balance beam test in a mouse model of early Parkinson’s disease

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment

    International Review of Neurobiology (Academic Press Inc.), pp. 103-143

2020

  1. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers

    Frontiers in Neuroscience, Vol. 14

2019

  1. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats

    Experimental Neurology, Vol. 322

  2. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation

    Neurobiology of Disease, Vol. 121, pp. 252-262

  3. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders

    International Review of Neurobiology (Academic Press Inc.), pp. 229-257

2016

  1. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors

    Experimental Neurology, Vol. 277, pp. 35-45

  2. Cannabinoids and Motor Control of the Basal Ganglia: Therapeutic Potential in Movement Disorders

    CANNABINOIDS IN HEALTH AND DISEASE (INTECH EUROPE), pp. 59-92

  3. Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats

    Neurobiology of Disease, Vol. 89, pp. 88-100

2014

  1. Interaction between the 5-HT system and the basal ganglia: Functional implication and therapeutic perspective in Parkinson's disease

    Frontiers in Neural Circuits, Vol. 8, Núm. MAR

  2. Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration

    Psychopharmacology, Vol. 231, Núm. 9, pp. 1913-1924

  3. Sistema serotonergikoaren eta gongoil basalen arteko elkarrekintza: inplikazio funtzionala eta terapiaren alderdia Parkinsonen gaixotasunean

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 27, pp. 9-27

2013

  1. Kannabisaren terapiarako erabilera mugimenduaren asalduretan

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 1, pp. 129-142

2012

  1. Endocannabinoid modulation of dopaminergic motor circuits

    Frontiers in Pharmacology, Vol. 3 JUN

2011

  1. Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats

    Psychopharmacology, Vol. 214, Núm. 2, pp. 379-389

2010

  1. Regulation of subthalamic neuron activity by endocannabinoids

    Synapse, Vol. 64, Núm. 9, pp. 682-698

  2. Two opposite effects of Δ9-tetrahydrocannabinol on subthalamic nucleus neuron activity: Involvement of GABAergic and glutamatergic neurotransmission

    Synapse, Vol. 64, Núm. 1, pp. 20-29

2008

  1. Involvement of subthalamic nucleus in the stimulatory effect of Δ9-tetrahydrocannabinol on dopaminergic neurons

    Neuroscience, Vol. 151, Núm. 3, pp. 817-823